RE:Response to this article appreciatedUnder this scrutiny then, every single Cannabis stock is a potential zombie stock save for TRUL which reported a healthy positive EBITDA. HEXO has hundreds of millions of dollars in the bank and I would wait until next Monday's earnings announcement before casting such a judgement. Even then...
HARJAY wrote: Would like to hear peoples reaction to this article written in the Globe and Mail.
Thanks,
Globe says give Hexo, others extra scrutiny
2018-12-10 08:58 ET - In the News
Also In the News (C-ADVZ) Advanz Pharma Corp
Also In the News (C-GUD) Knight Therapeutics Inc
Also In the News (C-KAT) Katanga Mining Ltd
Also In the News (C-POU) Paramount Resources Ltd (2)
The Globe and Mail reports in its Monday edition that the markets are on edge and trend followers are running for the exits. The Globe's Norman Rothery writes in the Inside the Market column that it is hard for companies to raise money while fear stalks the land. Mr. Rothery says they risk becoming zombie stocks that shamble around a bit before keeling over. He says even in good times, firms with negative earnings fare poorly and are, as a group, best avoided. For the current column, Mr. Rothery says he focused on stocks that are, potentially, in much more dire circumstances. To find them he looked at earnings before interest, taxes, depreciation and amortization or EBITDA. It is bad enough to fall into the red after paying normal and recurring business expenses such as interest and taxes and other expenses; it can be deadly having negative earnings even before these essentials are paid for. Companies with negative EBITDAs are in a particularly precarious position and may be zombies. Matters get worse when the markets tumble and it becomes next to impossible to borrow money or to sell stock. Mr. Rothery's potential zombie stocks are Hexo, Knight Therapeutics, Advanz Pharma, Katanga Mining and Paramount Resources.